3876938
Last Update Posted: 2019-03-15
Recruiting status is unknown
All Genders accepted | 18 Years + |
147 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Olanzapine Versus Aprepitant Based Antiemetic Regimen for High Emetic Chemotherapy
Aprepitant and olanzapine have been recommended for emesis prevention from highly emetogenic chemotherapy. We hypothesized that olanzapine may lead to less nausea compared to aprepitant based on previous study. However, data of combination of olanzapine and ondansetron is scarce.
Aprepitant and olanzapine have been recommended for emesis prevention from highly emetogenic chemotherapy. We hypothesized that olanzapine may lead to less nausea compared to aprepitant based on previous study. However, data on efficacy and adverse effects of combination of olanzapine and ondansetron which is only serotonin antagonist in Thai national essential drug list, is scarce. Also, we aims to assess the efficacy of olanzapine dosage of 5 mg which is more commonly used in Thai patients.
Eligibility
Relevant conditions:
Antiemetic for Highly Emetogenic Chemotherapy
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
locations
Contact Information
Overall Contact
Suthinee Ithimakin, MD
aesi105@yahoo.co.th
+6624194489
Data sourced from ClinicalTrials.gov